All articles by Manasi Vaidya
Manasi Vaidya is the lead editor for Pharmaceutical Technology where she covers the healthcare space. She writes features that look at the research, regulation and reimbursement of drugs with a focus on topics at the intersection of business and science. She is based in Brooklyn and an alum of New York University’s Science, Health and Environmental Reporting program.
Manasi Vaidya
@manasivaidya22
Magazine: What Rishi Sunak can do for the UK pharma industry
In this issue: The UK pharma sector’s wishlist for the new PM, the difficult outlook for chronic cardiovascular drug shortages, assessing the value of hemophilia gene therapies, and more
Early cell therapy successes start to turn the tide in lupus
CAR-Ts and MSCs are showing encouraging efficacy signals in treating lupus at a time when conventional approaches could also make a dent.
Magazine: Medicine in outer space
In this issue: Drug development and manufacturing in outer space, how inflation is driving sustainability in manufacturing, the future of remote regulatory assessments, and more.
CMO Moves: Regulatory catalysts for drug manufacturing-October
Pharmaceutical Technology analyses recent regulatory decisions and trial results that are expected to impact therapy manufacturing plans.
Magazine: Exploring the promise of billion-dollar KRAS drugs
In this issue: the promise of billion-dollar KRAS drugs, exploring nanorobots in drug delivery, foreign investments amplifying the nucleic acid therapeutics field, and more.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
CMO Moves: Regulatory catalysts for drug manufacturing-September
Pharmaceutical Technology does a roundup of recent regulatory decisions that impact drugs and the CMOs enlisted to manufacture them.
Foreign investments amplify the nucleic acid therapeutics field
FDI in the nucleic acid therapeutics field grew by 52% in 2021, recording a strong increase since the pandemic slowdown.
Magazine: NICE Makeover: a new look for the UK’s HTAs
In this issue, we take a look at changes at UK’s regulatory body NICE, new therapeutic approaches for prion diseases, and specialty generics production.
CMO Moves: Regulatory catalysts for drug manufacturing—August
Pharmaceutical Technology does a roundup of recent regulatory decisions that impact drugs and the CMOs enlisted to manufacture them.
UK health data collaboration paves the way to study long Covid symptoms
The University of Birmingham’s long Covid study is one of the success stories exploring the global potential of data-driven healthcare, writes Research Fellow Sarah Hughes.